Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab +/- SBRT for Oligometastatic Nasopharyngeal Carcinoma
NCT04944914Phase 3Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2021
- Primary completion
- Jun 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Started Jun 2021; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04944914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04944914.